AI Terminal
Evonik Industries AG
Regulatory Filings • Mar 31, 2016
150_rns_2016-03-31_6089bf32-9c22-42a7-9e40-e5d7b50efdfa.html
Regulatory Filings
Open in ViewerOpens in native device viewer
News Details
Corporate | 31 March 2016 09:00
Evonik Industries AG: Evonik starts up plant producing methionine source for shrimps
DGAP-News: Evonik Industries AG / Key word(s): Product Launch
2016-03-31 / 09:00
The issuer is solely responsible for the content of this announcement.
Evonik starts up plant producing methionine source for shrimps
– First plant for production of a methionine source for shrimps starts up in Antwerp.
– New product from Evonik increases efficiency and sustainability of crustacean aquaculture.
– Market launch of AQUAVI(R) Met-Met planned for mid-2016.
Essen. Evonik Industries has started up in Antwerp (Belgium) the world’s first production plant for a new methionine source specifically for shrimps and other crustaceans. AQUAVI(R) Met-Met, the dipeptide of two DL-methionine molecules, is expected to be launched on the market in mid-2016 and will be used as an aquaculture feed additive.
Dr. Reiner Beste, Chairman of the Board of Management of Evonik Nutrition & Care GmbH, says: “With AQUAVI(R) Met-Met we’re extending our range of feed amino acids for animal nutrition to include another specialty with high value for our customers. This further strengthens our position as a market and technology leader.”
“In AQUAVI(R) Met-Met we’re offering a cost-efficient and sustainable solution also for shrimp and crustacean farming,” says Dr. Emmanuel Auer, Head of the Animal Nutrition Business Line at Evonik. “In view of the growing global population and limited availability of resources, this appears to us to be vitally important.”
In 2015, no less than half of the fish, crustaceans, and shellfish consumed globally originated from aquaculture. Fishmeal being part of the feed as a protein source is a significant cost factor for farmers. Supplementation with amino acids allows significant reduction of the proportion of fishmeal in feeds, as Evonik has already demonstrated for fish farming. In addition, Evonik contributes to improved sustainability and conservation of biodiversity.
But shrimps and crustaceans have totally different feeding habits and digestive systems than, for example, fish and AQUAVI(R) Met-Met has been developed specially for them. It is significantly less water-soluble than DL-methionine and not so easily leached out of the feed. In the digestive tract of shrimps the dipeptide breaks down and methionine becomes available for protein synthesis at exactly the right time. As feeding trials in many countries have shown, just 0.56 kg of AQUAVI(R) Met-Met in 1,000 kg of shrimp feed results in the same growth as 1 kg of DL-methionine. This increases the efficiency and sustainability of shrimp farming.
AQUAVI(R) Met-Met has already been registered as a feed additive in many countries, with more to follow. The new methionine source will initially be available for shrimps and crustaceans but its efficiency is currently being tested for other species.
Evonik translates over 60 years of experience in manufacturing essential amino acids for animal nutrition into solutions that meet the evolving needs of its customers in over one hundred countries. As Evonik now expands its scope to innovative nutritional feed additive solutions beyond amino acids, customers can count on Evonik to take nutrient effectiveness ever further and keep delivering value along with consistent quality. Around the planet, Evonik products and services are and will continue to be key to producing healthy, affordable food with fewer natural resources and a smaller environmental footprint.
Company information
Evonik, the creative industrial group from Germany, is one of the world leaders
in specialty chemicals. Profitable growth and a sustained increase in the value of the company form the heart of Evonik’s corporate strategy. Its activities focus on the key megatrends health, nutrition, resource efficiency and globalization. Evonik benefits specifically from its innovative prowess and integrated technology platforms.
Evonik is active in over 100 countries around the world. In fiscal 2015 more than 33,500 employees generated sales of around EUR13.5 billion and an operating profit (adjusted EBITDA) of about EUR2.47 billion.
About Nutrition & Care
The Nutrition & Care segment is led by Evonik Nutrition & Care GmbH and contributes to fulfilling basic human needs. That includes applications for everyday consumer goods as well as animal nutrition and health care. This segment employed about 7,000 employees, and generated sales of around EUR4.9 billion in 2015.
Disclaimer
In so far as forecasts or expectations are expressed in this Investor Relations News or where our statements concern the future, these forecasts, expectations or statements may involve known or unknown risks and uncertainties. Actual results or developments may vary, depending on changes in the operating environment. Neither Evonik Industries AG nor its group companies assume an obligation to update the forecasts, expectations or statements contained in this release.
Contact:
| Tim Lange Head of Investor Relations Phone +49 201 177-3150 [email protected] |
| Evonik Industries AG Rellinghauser Straße 1-11 45128 Essen Germany Phone +49 201 177-01 Telefax +49 201 177-3475 www.evonik.com Supervisory Board Dr. Werner Müller, Chairman Executive Board Dr. Klaus Engel, Chairman Dr. Ralph Sven Kaufmann Christian Kullmann Thomas Wessel Ute Wolf Registered office Essen Registered court Essen local court Commercial registry B 19474 VAT ID no. DE 811160003 |
2016-03-31 Dissemination of a Corporate News, transmitted by DGAP – a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
| Language: | English |
| Company: | Evonik Industries AG |
| Rellinghauser Straße 1-11 | |
| 45128 Essen | |
| Germany | |
| Phone: | +49 (0) 201 177-01 |
| Fax: | +49 (0) 201 177-3475 |
| E-mail: | [email protected] |
| Internet: | www.evonik.com |
| ISIN: | DE000EVNK013, XS0911405784 |
| WKN: | EVNK01, A1TM7T |
| Indices: | MDAX |
| Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Hamburg, Hanover, Munich, Stuttgart; Terminbörse EUREX; Luxemburg |
| End of News | DGAP News Service |